Swiss pharma giant Novartis (NVS) has agreed to license a novel capsid generated from Voyager Therapeutics, Inc's (VYGR) capsid platform for use in a gene therapy program. Per Voyager, NVS will use this novel capsid for use in a gene therapy program against an undisclosed rare neurologic disease target. Shares of Novartis have risen 15.4% year to date compared with the industry's growth of 27%. Image Source: Zacks Investment Research Novartis' Deal With VYGR VYGR granted this capsid license to NVS per the t ...

Goldman Sachs has downgraded Novartis AG NVS, citing "limited value driving innovation catalysts in the near term." The analyst writes that continued earnings momentum has led to increases in revenue and profit forecasts for fiscal years 2024 and 2025 since the beginning of the year, thanks to upgraded fiscal year 2024 guidance provided in the first and second quarters of 2024. Also Read: Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs. Moreover, from a valuation s ...

Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Novartis (NVS) or Eli Lilly (LLY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores wor ...

Investors might want to bet on Novartis (NVS) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Since a changi ...

Novartis (NVS) announced positive data on the cholesterol drug Leqvio (inclisiran) from the late-stage VMONO study. Leqvio is the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (LDL-C). The drug is administered as a subcutaneous injection with an initial dose, another at three months, and then every six months. The drug is approved in several countries, including the United States, EU, Japan and China. Shares of Novartis have risen 18.8% year to date compar ...

Phase III V-MONO study met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C reduction1 Results add to growing body of evidence for Leqvio across the ASCVD continuum Data will be shared with regulatory agencies and presented at an upcoming medical meeting V-MONO is part of the 60,000-patient VictORION clinical trial program assessing Leqvio for primary and secondary ASCVD prevention Basel, August 28, 2024 – Novartis announced today pos ...

Novartis (NVS) recently suffered another setback in its attempt to block the entry of a generic version of its blockbuster heart drug Entresto. On Aug 12, judge Richard Andrews of The United States District Court For The District Of DelaWare denied Novartis' motion for preliminary injunction against MSN Pharmaceuticals Inc., MSN Laboratories Private Limited and MSN Life Sciences Private Limited for the launch of a generic version of Entresto. Several generic manufacturers are looking to launch a generic ver ...

Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. placebo (p<0.0001)1 Fabhalta is an inhibitor of the alternative complement pathway, activation of which is thought to contribute to the pathogenesis of IgAN1-4 Despite current standard of care, up to 50% of IgAN patients with persistent proteinuria progress to kidney failure within 10 to 20 years of diagnosis5-11 ...

VANCOUVER, BC, July 29, 2024 /PRNewswire/ -- USA News Group – How and what we eat is always changing. But for more and more people, the options to eat are drastically being reduced, due to rising amounts of food allergies. According to Food Allergy Research & Education (FARE), food allergy prevalence among children has been surging, up by 50% between 1997 and 2011, and up again by another 50% between 2007 and 2021. Research analysts at Spherical Insights projects strong growth in the Global Allergy Treatmen ...

Veronique D/iStock Editorial via Getty Images Following the Sandoz spin-off, Novartis (NYSE:NVS) (OTCPK:NVSEF) is now a pure player in innovative medicines, and we are not surprised to see a sharp margin increase. Here at the Lab, after a neutral rating recommendation held for years, we upgraded the company to a buy in April 2024. It was a good call, and Novartis' stock price is currently up by 14.96%, including the dividend payment (Fig 1). Our buy rating was backed by: Including Q2 2024, the company had r ...